Glenmark Pharma net profit rise 24%; Europe segment major contributor
Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals said, “In the first quarter of this financial year, nearly all our businesses have rebounded strongly and we have seen good growth across all operating regions except Latam.
The Europe business performed well due to strong growth witnessed by the UK subsidiary. Photo: Pixabay